Sanifit touts positive PhIIb data; REGENXBIO licenses Clearside Biomedical tech
→ Rare disease biotech Sanifit — which in June, raised nearly $81 million in Spain’s largest-ever private biotech fundraise — has announced that its international Phase IIb CaLIPSO study of SNF472 met its primary endpoint. The trial studied patients with end-stage kidney disease (ESKD) on hemodialysis and demonstrated a reduction in coronary artery calcium (CAC) volume in patients treated with SNF472 versus placebo. Detailed data will be presented at a medical conference.
→ As part of an existing agreement, REGENXBIO has exercised an option to license eye disease-focused Clearside Biomedical‘s SCS microinjector for the delivery of adeno-associated virus (AAV)-based therapeutics.
→ Following a 2018 pact, Ubiquigent and LEO Pharma have entered into an option agreement granting LEO access to two compounds — neither the type of compound nor the financial terms of the agreement were disclosed.